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Objective: Alzheimer’s disease occurs at a higher prevalence and an earlier age in individuals
with Down syndrome (DS) than typically developing individuals. However, diagnosing dementia in
individuals with intellectual disability remains a challenge due to pre-existing cognitive deficits. The aim
of this study was to investigate the validity and reliability of the Brazilian version of the Cambridge
Examination for Mental Disorders of Older People with Down’s syndrome and Others with Intellectual
Disabilities (CAMDEX-DS) for individuals with DS.
Methods: Two psychiatrists, working independently, evaluated 92 adults with DS X 30 years of age.
The concurrent validity of the CAMDEX-DS was analyzed in relation to the gold standard of esta-
blished international criteria. In a subgroup of 20 subjects, the concurrent validity of the CAMDEX-DS
was analyzed in relation to an independent objective assessment of cognitive decline over three years.
We analyzed the inter-rater reliability of cognitive assessment.
Results: The diagnostic accuracy of the CAMDEX-DS compared to the gold standard was 96.7%.
CAMDEX-DS-based diagnosis was considered consistent with cognitive decline. The probability of a
participant with dementia having cognitive decline was 83%. Inter-rater reliability for the participant
assessment was good, with a kappa of 4 0.8 for 93% of the CAMDEX-DS items.
Conclusion: The CAMDEX-DS can be considered the first valid and reliable instrument for evaluating
dementia in adults with DS in Brazil. Its use in such individuals could improve clinical practice and
research.
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Introduction
Down syndrome (DS) is a chromosomal anomaly caused
by the presence of an extra copy of chromosome 21.1
There are no official estimates of the prevalence and
incidence of DS in Brazil. However, in a collaborative study
involving 129 maternity hospitals in nine South American
countries (including Brazil), the live birth prevalence rate
of DS between 1995 and 2012 was reported as 0.12%.2
The estimated live birth prevalence of DS in the United
States was approximately 0.14% between 2004 and
2006.3 In England, the live birth prevalence of DS in 2010
was approximately 0.10%, 54% less than expected due
to screening programs and consequent abortions.4 The
characteristics of DS can include the physical phenotype
(hypotonia, short stature, protruding tongue, and flattened
facial appearance) and the clinical presentation of neurop-
sychological developmental delay that results in intellectual
disability in most individuals with DS.
There is a genetic link between DS and the early dev-
elopment of neuropathological features of Alzheimer’s
disease (AD) during adult life.5 That association is explai-
ned in part by the extra copy of chromosome 21, a chro-
mosome linked to the overexpression of certain proteins
related to the neurodegeneration process, including the
protein precursor of b-amyloid in the brain and superoxide
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dismutase 1.6 Thus, the triplicate copy of chromosome
21 leads to higher levels of proteins related to AD in
DS brains. In addition, DS is associated with premature
structural brain aging.7 Post-mortem studies have shown
that virtually all individuals with DS show neuropathological
signs of AD after reaching 40 years of age, including senile
plaques containing b-amyloid and neurofibrillary tangles.5
Because of the pathological similarity of AD among indi-
viduals with DS, research in this population has great
potential to advance understanding of AD in the general
population. Neuroimaging studies have demonstrated
b-amyloid deposition in individuals X 40 years of age with
DS, appearing first in the striatum, followed by prefrontal-
cingulo-parietal areas,8 and occurring prior to the onset of
dementia.9 However, the psychiatric and neuropsychologi-
cal features of the symptomatology of AD in DS can be
considerably different than those expected for the general
population.10
The specificities of the progression of AD in individuals
with DS, together with the presence of previous cogni-
tive deficits attributed to intellectual disability, make the
diagnosis of dementia in this population challenging.
It requires diagnostic assessment procedures that incor-
rate the specific information necessary to enable an accu-
rate clinical diagnosis. Instruments used to detect cognitive
decline in the general population are not suitable for
individuals with DS, because they are based on studies of
individuals with typical intellectual development and have
not been adapted for use in individuals with a low basal
level of cognitive and functional abilities. Although several
instruments have been developed or adapted for this
population in Europe and the United States,11-14 none have
been translated to Portuguese or validated for use in Brazil.
Consequently, there are no instruments available for
diagnosing dementia in individuals with DS in Brazil. The
Cambridge Examination for Mental Disorders of Older
People with Down’s syndrome and Others with Intellectual
Disabilities (CAMDEX-DS)11 is a diagnostic instrument
consisting of an objective neuropsychological assessment
of the individual with DS (CAMCOG-DS) and a detailed
interview to be conducted with an informant, which allows a
decline from the individual’s best level of functioning to be
established.15 The CAMDEX-DS is designed to provide
support for good clinical and research practices. In a review
including an analysis of instruments used in recent years,10
the CAMDEX-DS was the only diagnostic assessment tool
that was based on standardized international criteria, was
designed for use in individuals with intellectual disability
and AD, is administered to an informant, and includes a
direct cognitive assessment of the subject. The CAMDEX-
DS was found to be one of the most widely used instru-
ments in studies in this area. In this paper, we report on the
validity and reliability of the CAMDEX-DS for diagnosing
dementia in a population of individuals with DS in Brazil.
Methods
Ethics
The study was approved by the research ethics committee
of the Hospital das Clı́nicas, Universidade de São Paulo
(USP), and was registered with the national committee
for ethics in research through Plataforma Brasil (CAAE
no. 37381414.8.0000.0065).
Study design
This was a cross-sectional, case-control study with longi-
tudinal analysis for a subgroup of participants.
Setting
The study was carried out by the Programa Terceira
Idade (PROTER) of the Instituto de Psiquiatria, Hospital
das Clı́nicas, Faculdade de Medicina, USP, in partnership
with the Associação de Pais e Amigos dos Excepcionais
de São Paulo (APAESP) and the Associação para o
Desenvolvimento Integral do Down (ADID). Assessments
were performed at the hospital or at one of the involved
associations, depending on the logistics (i.e., the most
convenient location for the participants and their families).
In some cases, when a participant’s or informant’s mobility
was limited, parts of the evaluations were performed in
their home. In all cases, the assessments were carried
out in silent rooms arranged for the evaluation. When the
assessments were divided over testing sessions, the time
between them was 1 or 2 weeks at most.
Participants
All participants met the ICD-10 criteria for a diagnosis of
DS (code, Q90) and wereX 30 years of age. The majority
of the participants were or had previously been enrolled
in APAESP or ADID. Eight additional individuals were
included in the study after meeting participants. APAESP
and ADID identified eligible participants and provided a
list of contacts. The objectives of the study were explai-
ned to all participants in a simple, concrete manner, and
any questions or concerns had were addressed. Due to
their intellectual disability, written informed consent was
obtained not only from the participants, but their legal
guardians as well. Figure 1 illustrates the process of
selecting subjects for inclusion in the study.
CAMDEX-DS
The CAMDEX-DS11 is a version of the CAMDEX scale,16
modified and adapted for DS, that incorporates the
specific information necessary to enable an accurate
clinical diagnosis and to facilitate the differential diagnosis
of any observed decline in this population. It takes into
account pre-morbid difficulties, establishing decline from
the individual’s best level of functioning. The CAMDEX-DS
includes informant and participant interviews with objective
assessment of cognitive function, as well as a standardized
schedule for recording observations, physical examination
findings, and laboratory test results. The domains covered
in the CAMDEX-DS informant interview are: Participant’s
Best Level of Functioning (education and employment,
basic skills, and independent living); Cognitive and
Functional Decline (everyday skills, memory, orienta-
tion, general mental functioning, language, perception,
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praxis, executive functions, personality, behavior, and
self-care); Current Mental Health (depression, anxiety,
paranoid illness, clouding/ delirium, and substance abuse);
and Current Physical Health (physical disability, hypothyr-
oidism, cerebrovascular problems, other physical illness,
and medication).
Bottino et al. translated the CAMDEX to Portuguese
and culturally adapted and validated it for use in Brazilian
adults from the typically developing population with
dementia.17 The reliability of the syndromic diagnosis of
dementia, as determined by calculating the kappa statistic
(k), was excellent (k = 0.94) and that of the etiological
diagnosis was good (k = 0.83), both with a p-value of
0.001. In Brazil, the Portuguese-language version of the
CAMDEX has shown good applicability and is widely used
by clinicians and researchers.18-20
The original CAMDEX-DS validation study involved 74
individuals X 30 years of age with DS in England.11 For
diagnosing AD, the CAMDEX-DS showed a specificity of
0.94 and a sensitivity of 0.88. The inter-rater reliabi-
lity was considered good (k 4 0.8) for 91% of the items
and fair (k 4 0.6) for all of the items collectively. The
CAMDEX-DS has also been validated for use in Spain.21
It is now widely used in studies of individuals with DS and
intellectual disability.7,8,22,23
CAMCOG-DS
The Cambridge Cognitive Examination adapted for indi-
viduals with Down Syndrome (CAMCOG-DS) is a concise
group of neuropsychological tests included in the CAM-
DEX-DS. It was designed to ensure that most individuals
with DS score above the test floor, thus improving the
detection of cognitive decline. Some questions from the
original CAMCOG were removed after proving to have
a high floor effect; in other CAMCOG-DS questions, the
participant can acquire a half-score because the inter-
viewer is allowed to provide clues as needed. The
CAMCOG-DS comprises subscales for the following
domains: orientation; language (comprehension and
expression); memory (new learning, remote, and recent);
attention; praxis (drawing complex figures and the ability
to carry out complex tasks); abstract thinking; and per-
ception. The maximum total score on the CAMCOG-DS is
109 points.
Hon et al.24 showed that the CAMCOG can differenti-
ate between older and younger individuals with DS. The
authors concluded that, with minor modifications, the
CAMCOG is a useful test for evaluating areas of cognitive
function that are known to deteriorate in dementia. In addi-
tion, the decline in CAMCOG scores was greater in parti-
cipants who had been diagnosed with dementia than in
those who had not.
The CAMCOG-DS is a reference for studies investigat-
ing cognitive processes in adults with intellectual dis-
ability.23,25-27 In one study of individuals with DS in Brazil,
a longitudinal comparison of individual performance on
the CAMCOG was found to enrich the analysis of cog-
nitive decline.28
Translation and cultural adaptation of the CAMDEX-DS
for use in Brazil29
The content validation of the CAMDEX-DS involved the
following steps: initial translation to Portuguese; cultural
adaptation with assistance of a multidisciplinary team
Figure 1 Flow chart of the participant inclusion process. ADID = Associação para o Desenvolvimento Integral do Down;
APAESP = Associação de Pais e Amigos dos Excepcionais de São Paulo; DS = Down syndrome.
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assembled from the PROTER Research Group; evalua-
tion of the cognitive portion of the translated, adapted
version for equivalence (semantic, idiomatic, conceptual,
and experimental) and comprehension by two neuropsy-
chologists, working independently; suggestions made by
the two neuropsychologists; re-adaptation taking those
suggestions into account; re-evaluation of the new version;
back-translation into the original English by a free-lance
bilingual translator with no access to the original version;
evaluation (by the original authors) of the equivalence of
the modified cognitive portion; and a pilot test involving
10 adults with DS who did not participate in the subsequent
validation study. The pilot was considered comprehensive,
requiring no further modifications.
Diagnostic categories
We established three diagnostic categories: AD, prodro-
mal dementia, and stable cognition. Prodromal dementia
was defined as evidence of cognitive decline that was
more severe than that expected for the stable cognition
group, but not severe enough to meet the criteria for AD.
The categories were established separately based on the
CAMDEX-DS guidelines and the gold standard.
Diagnostic assessment using the CAMDEX-DS
The CAMDEX-DS questionnaire was administered by a
trained psychiatrist who made the diagnosis based on the
CAMDEX-DS guidelines and the CAMCOG-DS results,
but was blinded to all other assessments and information.
CAMDEX inclusion criteria for AD indicate a decline in:
a) everyday skills; b) memory; and c) one of the follow-
ing: general mental functioning, language, praxis, object
recognition, executive function, and/or personality and
behavior. The duration of the changes must be greater
than six months with gradual onset and no evidence of
clouding/delirium, signs of vascular dementia, or sec-
ondary dementia. The time required to administer the
CAMDEX-DS questionnaire to the informant varied from
40 to 60 minutes.
Gold standard diagnostic procedure
A psychiatrist trained in geriatrics and intellectual dis-
ability performed the gold standard diagnostic evaluation.
Because of the challenge of using a gold standard for
diagnosing dementia in individuals with DS in Brazil,
the evaluation was based on criteria established in
the Diagnostic Manual – Intellectual Disability,30 the
DSM-531 and the ICD-10,32 with the rater blinded to the
CAMDEX-DS-based diagnosis. In addition to a struc-
tured clinical interview, the rating psychiatrist applied
the Informant Questionnaire on Cognitive Decline in the
Elderly,33 the Neuropsychiatric Inventory,34 and the
Frontal System Behavior Scale.35 The rater also had access
to neuropsychological assessment data other than the
CAMCOG score, as well as to all available medical records.
The time required for the gold standard diagnosis varied
from 90 minutes to 120 minutes.
Neuropsychological assessment
A neuropsychologist applied the CAMCOG-DS and
the Wechsler Abbreviated Scale of Intelligence.36 The
total time required to apply the instruments varied from
90 minutes to 120 minutes. When necessary, the evalua-
tion was divided into two sessions with a maximum of
1 week between them.
Concurrent validity between the CAMDEX-DS and the
gold standard
The concurrent validity between the CAMDEX-DS and
the gold standard clinical diagnostic procedure was esta-
blished through the agreement level of diagnoses made
by each method.
Concurrent validity between the CAMDEX-DS and
objective assessment of cognitive decline over 3 years
We examined the concurrent validity between the CAM-
DEX-DS and an objective assessment of cognitive decline
for 20 subjects in our sample who had participated in a
previous longitudinal study by our team involving the
CAMCOG.28 The second CAMCOG assessment was
performed when the CAMDEX-DS was applied. Cogni-
tive decline was defined as one standard deviation (SD)
below the mean change in CAMCOG score.11
Inter-rater reliability of the CAMCOG-DS
For the inter-rater reliability analysis of the CAMCOG-DS,
the responses of 20 individuals with DS were rated simu-
ltaneously and independently by the neuropsychologist
who conducted the cognitive assessment and a psychia-
trist who observed the assessment. The results of the
items and subscales were compared for each participant.
Statistical analysis
To determine the concurrent validity between the gold
standard diagnosis and the CAMDEX-DS-based diagno-
sis, we calculated type I errors, type II errors, sensitivity,
specificity, accuracy, predictive value, and the likelihood
ratio. We also analyzed the agreement between the two
variables by calculating the kappa statistic. To determine
inter-rater reliability, the level of agreement between the
interviewers was also analyzed by calculating the kappa
statistic. To analyze the concurrent validity between
the CAMDEX-DS-based diagnosis and the cognitive
decline assessment, we compared the groups’ 95% con-
fidence intervals (95%CI) for cognitive decline, cross-
tabulated the data, performed Fisher’s exact test, and
calculated the odds ratio (OR). For the sample as a whole,
assumptions of homogeneity of demographic features
among groups (stable cognition vs. prodromal dementia
vs. AD) were verified with the Kruskal-Wallis test (for
continuous variables) or Fisher’s exact test (for catego-
rical variables). The level of statistical significance was
set at p o 0.05. All selected data were tabulated with the
Braz J Psychiatry. 2019;41(3)
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Research Electronic Data Capture (REDCap) program37
and analyzed with SPSS version 14.
Results
Demographic data
Table 1 shows the demographic characteristics of the
sample as a whole, as well as comparisons among the
groups. The overall prevalence of AD was 11.9%, whereas
that of prodromal dementia was 19.6% (based on the gold
standard).
All informants had known the participant for at least
10 years, and the majority were family members or pri-
mary caregivers. We found that there were considerably
more primary caregivers who were not the parents in the
prodromal dementia and AD groups than in the stable
cognition group.
Concurrent validity between the CAMDEX-DS and the
gold standard
The analysis of concurrent validity between CAMDEX-DS
and the gold standard included 92 individuals. Compared
to the gold standard, the CAMDEX-DS had a specificity
for dementia (proportion of individuals accurately identi-
fied as having no dementia) of 98.4% and a sensitivity
for AD (proportion of individuals accurately identified as
having AD) of 100%. In addition, the CAMDEX-DS had a
sensitivity of 88.9% for diagnosing prodromal dementia.
Therefore, the overall accuracy of the CAMDEX-DS was
96.7%, i.e., the proportion of true positives and true nega-
tives among all evaluated cases (Table 2). The predictive
value or precision (ratio of true positives to combined true
and false positives) of the CAMDEX-DS-based AD diagno-
sis in this sample of individuals X 30 years of age with DS
was 84.6%, whereas it was 94.1% for the CAMDEX-DS-
based prodromal dementia diagnosis. The kappa statistic
for the agreement between the CAMDEX-DS and the gold
standard was 0.93 (p o 0.05).
Concurrent validity between CAMDEX-DS and cognitive
decline over three years
The CAMDEX-DS-based diagnosis was cross-tabulated
with a decline in CAMCOG scores over a 3-year period in
a subgroup of 20 participants. At baseline, none of them
was diagnosed with dementia. Of those 20 participants,
12 (60%) were male. The mean age of the participants
was 47.8 years (SD 6.81), ranging from 39 to 60 years.
Those whose CAMCOG score declined 4 5.8 points – at
least 1 SD (9.38) from the mean change for the group
(-3.5) – were significantly more likely to be diagnosed with
AD or prodromal dementia (p = 0.049, Fisher’s exact
test). Of the 11 participants in the stable cognition group,
only one (9.1%) showed such a decline. Among the six
participants diagnosed with prodromal dementia, the
CAMCOG score declined by 4 5.8 points in two (33.3%),
by o 5.8 points in two (33.3%), and improved overall by
3 points in two (33.3%). The CAMCOG score of all three
Table 1 Demographic and clinical characteristics of the participants
Characteristic








Age (years), mean (SD) 42.45 (8.51) 38.84 (7.43) 44.89 (6.22) 53.36 (8.13) o 0.001
Maternal age at birth (years), mean (SD) 34.18 (7.70) 33.27 (7.42) 34.18 (9.28) 39.80 (4.21) 0.092
Intellectual disabilityw 0.009
Mild 34 (37.8) 28 (44.4) 4 (23.5) 2 (20.0)
Moderate 34 (37.8) 24 (38.1) 9 (52.9) 1 (10.0)
Severe 22 (24.4) 11 (17.5) 4 (23.5) 7 (70.0)
Male, gender 59 (64.1) 41 (65.1) 10 (55.6) 8 (72.7) 0.632
Education 0.261
None 8 (8.7) 4 (6.3) 4 (22.2) 0 (0)
Specialized school 60 (65.2) 40 (63.5) 11 (61.1) 9 (81.8)
Specialized and regular school 21 (22.8) 17 (27.0) 2 (11.1) 2 (18.2)
Regular school 3 (3.3) 2 (3.2) 1 (5.6) 0 (0)
Relationship with informant 0.009
Parent 53 (57.6) 42 (66.7) 9 (50.0) 2 (18.2)
Sibling or other 39 (42.4) 21 (33.3) 9 (50.0) 9 (81.8)
Hypothyroidism 48 (75.0) 30 (47.6) 13 (72.2) 5 (45.4) 0.160
Epilepsy 13 (20.3) 7 (11.1) 2 (11.1) 4 (36.3) 0.082
Sedentary life style 36 (39.1) 19 (30.2) 9 (50.0) 8 (72.7) 0.017
Medication that affects the CNS 20 (21.7) 9 (14.3) 4 (22.2) 7 (63.6) 0.002
Family history of AD 23 (25.0) 12 (19.0) 5 (27.8) 6 (54.5) 0.044
Data presented as n (%), unless otherwise specified.
AD = Alzheimer’s disease; CNS = central nervous system; SD = standard deviation.
*Comparison among groups (stable cognition, prodromal, and AD) was performed using the Kruskal-Wallis test for continuous variables and
Fisher’s exact test for categorical variables.
w n=90 because two cases were classified as unspecified intellectual disability (ICD-10 code F79) and were excluded: one from the AD group
and one from the prodromal dementia group.
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individuals diagnosed with AD declined by 4 5.8 points.
The 95%CI for cognitive decline did not intersect between
the stable cognition and AD groups (95%CI -2.25 to 4.07
vs. -39.39 to -4.61), which indicates that there is a
distinction between them. This was not the case for the
prodromal dementia group (95%CI -7.15 to 2.48), indicat-
ing that it is an intermediate group between the stable
cognition and AD groups. For the AD and prodromal
groups together, the 95%CI for cognitive decline over
the three years ranged from -17.38 to -0.39. The probability
of a 4 5.8 point decline in CAMCOG score was 83% for
those diagnosed with AD or prodromal dementia (OR =
12.5, 95%CI 1.08 to 143.43).
Inter-rater reliability of the CAMCOG-DS
For the inter-rater reliability analysis, we collected data on
a subgroup of 20 participants, eight (40%) of whom were
male. The mean age was 44.80 years (SD 7.51 years;
range, 32-60 years). One (5%) was diagnosed with AD
and six (30%) with prodromal dementia. Ten (50%) had
mild intellectual disability, nine (45%) had moderate
intellectual disability, and one (5%) was classified as
having unspecified intellectual disability due to cognitive
decline without a prior classification. Although the inter-
rater agreement was excellent (k 4 0.90, p o 0.001) for
most (87%) of the CAMCOG-DS items, it was lower (k =
0.80-0.90, p o 0.001) for three items (6%). Table 3
presents items for which the kappa statistic was o 0.8.
Discussion
Diagnosing dementia in individuals with a history of
cognitive impairment, such as people with DS, continues
to be a challenge due to the lowered baseline functioning
and pre-existing abnormalities in brain development. In
this study, we have demonstrated that the Portuguese-
language version of the CAMDEX-DS, adapted for use in
Brazil, is highly accurate for diagnosing dementia and
identifying cognitive and functional prodromal decline in
individuals with DS. The CAMDEX-DS could detect nearly
all of the cases of prodromal dementia and AD that were
diagnosed with the gold standard method, providing a faster
and standardized interview. Of the participants testing
positive for AD on the CAMDEX-DS, 84% were considered
true positive, as were 94% of those testing positive for
prodromal dementia. The ability of the CAMDEX-DS to
refute other diagnoses was also good. The level of agree-
ment between the CAMDEX-DS-based and gold standard
diagnoses was similar to that found in the validation study
conducted in Spain.21 The majority of the CAMCOG-DS
items presented excellent inter-rater reliability (k 4 0.8).
We found that age had a strong influence on the
selected variables, which can be explained by the known
associations among age, cognitive decline, and AD.38
The stable cognition group was considerably younger
than the prodromal dementia group, just as the prodromal
dementia group was younger than the AD group. Pro-
dromal dementia appeared as a transitional stage in this
population, as is the case for mild cognitive impairment in
the general population.39 The key difference is that the
age of onset for cognitive decline and dementia in this
population is nearly 20 years earlier than that reported for
the general population, which corroborates the findings of
previous studies showing that individuals with DS present
early aging.40
Despite the excellent validity and reliability observed for
the CAMDEX-DS, the importance of training in its appli-
cation and interpretation should be stressed. Although the
CAMDEX-DS guides the investigation to elucidate aspects
necessary for an adequate evaluation, a CAMDEX-DS-
based diagnosis still relies on clinical judgement. Just as
with the use of the CAMDEX in the general population,
there is no formula or cutoff score that directly indicates
a specific diagnosis; knowledge in the area and a clinical
appraisal are of fundamental importance. Nevertheless,
at the end of the questionnaires, the CAMDEX provides a
guide for clinical diagnosis, with information on universally
Table 2 Cross-tabulation of the CAMDEX-DS and gold standard diagnoses
Gold standard diagnosis
Variable/CAMDEX-DS diagnosis AD Prodromal dementia Stable cognition Total
Sample as a whole (n)
AD 11 2 0 13
Prodromal dementia 0 16 1 17
Stable cognition 0 0 62 62
Total 11 18 63 92
Diagnosis (%)
AD 100.0 11.1 0.0 14.1
Prodromal dementia 0.0 88.9 1.6 18.5
Stable cognition 0.0 0.0 98.4 67.4
Total 100.0 100.0 100.0 100.0
Total (%)
AD 11.9 2.2 0.0 14.1
Prodromal dementia 0.0 17.4 1.1 18.5
Stable cognition 0.0 0.0 67.4 67.4
Total 11.9 19.6 68.5 100.0
AD = Alzheimer disease; CAMDEX-DS = Cambridge Examination for Mental Disorders of Older People with Down syndrome and Others with
Intellectual Disabilities.
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accepted diagnostic criteria and guidelines for classifying
the severity of dementia, thus offering support for this pro-
cess. It is also of note that a CAMDEX evaluation places
great emphasis on the information provided by the infor-
mant, thus requiring this person to have known the indi-
vidual for quite some time, preferably having seen him/her
quite frequently. Our finding that the number of primary
caregivers who were not the parents tended to increase in
parallel with an increase in the degree of dementia is pro-
bably attributable to the comparable relationship between
the age of the participants and their cognitive decline: as
individuals with DS age, their parents are more likely to die
or become unable to provide care. This underscores the
need to adapt care and public policies targeting this popu-
lation in developing countries such as Brazil.
Our study has some limitations that should be con-
sidered. First and foremost is the lack of a validated
instrument for diagnosing AD in individuals with DS in
Brazil to use as a gold standard. However, to our know-
ledge, this is the first study attempting to determine the
validity and reliability of a specific instrument for AD in
individuals with DS in Brazil. We attempted to reduce this
gap by using internationally recognized criteria adapted
for this population,30 as well as by determining its validity
as measured against the cognitive decline observed in
a subsample. We attempted to conduct an accurate
investigation of all areas known to deteriorate in adults
with DS and included instruments that have previously
shown good applicability.28 Another limitation of our study
is that both psychiatrist raters received the same training
regarding intellectual disability and aspects related to
aging in DS. Although we consider this training essential
for both assessments, it could have been at least partially
responsible for the high agreement rates. We believe that
both raters had the knowledge necessary to make an
accurate clinical evaluation, despite using different instru-
ments for data collection and different diagnostic guide-
lines. Another limitation is that sedentary lifestyle, intellec-
tual disability, the use of medication affecting the central
nervous system, and a family history of AD all showed
significant differences among groups. Our cross-sectional
study design prevented us from distinguishing the nature
of those associations. For example, it is possible that
the participants with prodromal dementia or AD became
sedentary due to a functional decline. The degree of
intellectual disability could be related to the level of cogni-
tive reserve, as well as our inability to determine whether
such deficits were associated with psychiatric symptoms.
The use of medication that affects the central nervous
system might be due to treatment for neuropsychiatric
Table 3 Inter-rater reliability study: Cambridge Cognitive Examination adapted for individuals with Down Syndrome
(CAMCOG-DS) items with a kappa statistic o 0.8
CAMCOG-DS item/version Content kappa p-value
187 Language-Definition 0.583 0.002
Original What is a bridge?
A general (abstract) definition scores 2 and a specific or limited definition scores 1.
O Goes across river (2)
O Cross the bridge (1)
O Incorrect (0)
Brazilian Portuguese O que é uma ponte?
Definição geral (abstrata) pontua 2 e uma definição limitada pontua 1.
O Atravessa um rio (2)
O Atravessa a ponte (1)
O Incorreto (0)
202 Praxis-Copy 0.773 0
Original Copy this picture (3D house).
Tick each component successfully completed and enter number under Total.
O Outline of house
O Windows, doors, and chimney in correct position
O 3D representation
Brazilian Portuguese Copie esta forma (casa).
Marque cada componente completado com sucesso e anote o número de
componentes no Total.
O Perfil de casa
O Janela, porta e chaminé nas posições certas
O Representação 3D
216 Visual Perception 0.615 0.032
Original Who is this? (Queen/Pope, Archbishop, Bishop)
Score as correct if picture is recognized.
Correct name is not required, but record any answer that does not correspond
exactly to the examples given.
Brazilian Portuguese Quem é este? (Pelé/Papa, Bispo)
Pontue como correto se a figura for reconhecida.
O nome correto não é requerido, mas registre qualquer resposta que não
corresponda exatamente aos exemplos dados.
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symptoms related to AD. Data in the literature suggest
that a family history of AD is a risk factor for developing
the disease in the general population.41 However, in our
sample, the appearance of cognitive decline symptoms
might have focused more attention on family history.
Furthermore, as with any other cognitive test applied in
this population, the CAMCOG-DS has limited diagnostic
value in a single evaluation. Without baseline measure-
ments, it is impossible to determine to what extent cog-
nitive malfunction is a consequence of a previous deficit
or of another disorder that may affect cognitive ability,
which thus might not necessarily be a decline. Never-
theless, a cognitive decline over time provides a useful
complement to the diagnostic and support process, as
evidenced in our longitudinal comparison, despite the small
sample size. In addition, although most CAMCOG-DS
items presented excellent inter-rater agreement, three
items in particular were more difficult to score, perhaps
because they presented more abstract concepts. A more
detailed definition of the scores may help improve the
evaluation of these items. The small number of participants
in our longitudinal analysis of objective cognitive decline is
another limitation of our study. Further studies are needed
to explore these questions.
To our knowledge, this is the first study to validate an
instrument for detecting AD and cognitive decline in
individuals with DS in Brazil. Given the challenges of early
detection of neurodegenerative diseases in individuals
with DS, there is a need for an assessment instrument
that contemplates the specificities of the aging process in
this population. The CAMDEX-DS appears to be a valid
and reliable instrument for facilitating the early identifica-
tion of cognitive and functional changes, as well as for
refining the diagnosis of individuals with DS in Brazil, thus
allowing care to be adapted to their demands and sup-
porting further research in this area.
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